ISSN 2149-2263 | E-ISSN 2149-2271 Home      
 
Volume : 23 Issue : 1
Current Issue Archive Popular Article Ahead of Print

   
Quick Search





 
Pravastatin therapy fails to suppress post-PCI inflammatory response measured by serum neopterin and CRP levels [Anatol J Cardiol]
Anatol J Cardiol. 2011; 11(3): 207-212 | DOI: 10.5152/akd.2011.054  

Pravastatin therapy fails to suppress post-PCI inflammatory response measured by serum neopterin and CRP levels

Hüseyin Bozbaş1, Serdar Mermer2, Aylin Yıldırır1, Didem Konaş1, İlyas Atar1, Alp Aydınalp1, Bülent Özin1
1Department of Cardiology, Faculty of Medicine, Başkent University, Ankara, Turkey
2Cardiology Clinic, Akay Hospital, Ankara

Objective: Percutaneous coronary intervention (PCI) is known to induce both local and systemic inflammatory states. In addition to lowering lipid levels, statins exert well-proven anti-inflammatory effects. We investigated the effects of pravastatin on serum C-reactive protein (CRP) and neopterin levels in the short term after elective PCI. Methods: In this randomized prospective study, 93 patients undergoing elective PCI were enrolled. Group 1 (n=30) received pravastatin at a dose of 10 mg/day, Group 2 (n=29) was given 40 mg/day, and Group 3 (n=34) served as the control group and received no lipid-lowering drugs. Blood samples were drawn before and after PCI to measure serum CRP and neopterin levels. Differences among the groups for continuous variables were evaluated by the ANOVA and the Kruskal-Wallis test as appropriate. The Chi-square test was used for comparison of categorical variables. Results: Demographic features and the characteristics of the PCI, including the number of vessels and lesions and the duration and number of inflations, did not differ among groups (p>0.05). Serum CRP and neopterin levels were significantly increased after PCI (p<0.001). Mean serum neopterin levels before and after the PCI were as follows: Group 1: 13.3±5.9 vs 22.8±15.4 nmol/L, Group 2: 16.9±10.2 vs 22.0±14.9 nmol/L, controls: 15.2±11.9 and 18.8±11.5nmol/L. Prior pravastatin therapy had no significant effect on these inflammatory markers (F=0.5, p=0.6). Conclusion: Percutaneous coronary intervention induces a pronounced inflammatory response. The pre-procedural administration of 2 different doses of pravastatin seems not enough to suppress this inflammation at the short-term follow-up. Further trials are needed to clarify this issue.

Keywords: Statin, C-reactive protein, neopterin, percutaneous coronary intervention


Hüseyin Bozbaş, Serdar Mermer, Aylin Yıldırır, Didem Konaş, İlyas Atar, Alp Aydınalp, Bülent Özin. Pravastatin therapy fails to suppress post-PCI inflammatory response measured by serum neopterin and CRP levels. Anatol J Cardiol. 2011; 11(3): 207-212


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share


Similar articles
PubMed
Google Scholar




 
 
KARE Publishing | Copyright © 2018 Turkish Society of Cardiology